-Synuclein is a pathological component of Parkinson's disease by constituting the filamentouscomponent of Lewy bodies. Phthalocyanine (Pc) effects on the amyloidosis of
-synuclein have beenexamined. The copper complex of phthalocyanine tetrasulfonate (PcTS-Cu
2+) caused the self-oligomerization of
-synuclein while Pc-Cu
2+ did not affect the protein, indicating that introduction ofthe sulfonate groups was critical for the selective protein interaction. The PcTS-Cu
2+ interaction with
-synuclein has occurred predominantly at the N-terminal region of the protein with a
Kd of 0.83
Mapart from the hydrophobic NAC (non-A
component of Alzheimer's disease amyloid) segment.Phthalocyanine tetrasulfonate (PcTS) lacking the intercalated copper ion also showed a considerable affinitytoward
-synuclein with a
Kd of 3.12
M, and its binding site, on the other hand, was located at theacidic C-terminus. These mutually exclusive interactions between PcTS and PcTS-Cu
2+ toward
-synucleinresulted in distinctive features on the kinetics of protein aggregation, morphologies of the final aggregates,and their in vitro cytotoxicities. The PcTS actually suppressed the fibrous amyloid formation of
-synuclein,but it produced the chopped-wood-looking protein aggregates. The aggregates showed rather low toxicity(9.5%) on human neuroblastoma cells (SH-SY5Y). In fact, the PcTS was shown to effectively rescue thecell death of
-synuclein overexpressing cells caused by the lactacystin treatment as a proteasome inhibitor.The anti-aggregative and anti-amyloidogenic properties of PcTS were also demonstrated with alcoholdehydrogenase, glutathione
S-transferase, and amyloid
/A4 protein under their aggregative conditions.The PcTS-Cu
2+, on the other hand, promoted the protein aggregation of
-synuclein, which gave rise tothe fibrillar protein aggregates whose cytotoxicity became significant to 35.8%. Taken together, the dataprovided in this study indicate that PcTS/PcTS-Cu
2+ could be considered as possible candidates for thedevelopment of therapeutic or prophylactic strategies against the
-synuclein-related neurodegenerativedisorders.